Viracor-IBT Laboratories, Inc.’s Zika Virus RT-PCR Test Receives Emergency Use Authorization From the FDA
Test Provides U.S. Physicians and Patients Same Day Results and the Option to Test Urine Alongside Blood
The National Kidney Registry (NKR) and Viracor-IBT Laboratories announced today a partnership to streamline pre-transplant serology testing for kidney donors. The NKR selected Viracor-IBT as the national laboratory to perform infectious disease screening for its 75 member centers. Fast and accurate preoperative serology testing reduces paired kidney exchange or “swap” failures and increases the number of patients transplanted in NKR facilitated swaps. With so many lives involved, time is of the essence and streamlined logistics are critical; delayed test results can delay transplants.
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, is pleased to present the results from a recent study1 published in Transplantation2, showing that Viracor-IBT’s ImmuKnow, the FDA-cleared immune cell function assay that detects cell-mediated immunity in immunosuppressed patients, helps improve outcomes in solid organ transplant (SOT) patients. The study demonstrated that the ImmuKnow assay provided additional data which helped optimize immunosuppression, and ultimately improve patient survival rate3.
Viracor-IBT is excited to partner with USA Today's Transplants: The Gift of Life, an annual supplement bringing attention to transplantation and the organ donation industries united work to raise awareness about gifting one's organs in order to help save the lives of others.
9 May 2014
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, has signed a definitive agreement to acquire ViraCor-IBT Laboratories, Inc. (VIBT) from majority owner Ampersand Capital and other shareholders for approximately $255m, subject to post-closing adjustments.
Combined diagnostic expertise will help more U.S. transplant patients
Viracor-IBT Laboratories, Inc. announced today it has closed on its previously announced transaction to purchase assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation. NIT made the decision to transfer its laboratory operations to Viracor-IBT to perpetuate the mission of its foundation, build on the legacy of its laboratory operations, and to provide testing services to more transplant patients across the U.S.
Expands laboratory operations to help more U.S. transplant patients
Viracor-IBT Laboratories, Inc. announced today it has signed a definitive agreement to purchase all assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation.
Utilizes ImmuKnow® immune monitoring assay to enhance transplant patient care.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of CylexTM, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
New Alpha-Gal IgE assay is the first to specifically detect antibodies associated with a delayed-onset allergic reaction to beef, pork, and lamb, the development of which has been linked to tick bites.
New testing service is the first to detect and measure deadly Invasive Pulmonary Aspergillosis
Scientists from Viracor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year’s American College of Allergy, Asthma and Immunology’s Annual Scientific Meeting in Miami, Florida.
New suite of tests identifies 2009 Influenza A H1N1 ("swine flu"), additional influenza subtypes and other common respiratory viruses, assisting physicians in improving patient care and ensuring appropriate antiviral use.
Combined company draws on latest scientific research to provide the most accurate, reliable and comprehensive immunology and infectious disease tests available.
New test will assist in the earlier diagnosis of Progressive Multifocal Leukoencephalopathy, a serious brain infection exclusively caused by JCV.
New Service Provides Comprehensive Detection of Antiviral Resistant Virus Strains in Just Three Days, Helping Physicians Treat Patients Quickly, Improve Patient Outcomes and Reduce Healthcare Costs.
Unique clinical reference and research lab offers complex respiratory virus testing that improves patient care by allowing doctors to identify an infection quickly and accurately.
New testing service saves lives and reduces healthcare costs
Service begins with the introduction of two tests Platelia Aspergillus EIA and Fungitell β-D Glucan
Award Recognizes Entrepreneurial Excellence in Life Sciences Category
National Clinical Reference Laboratory Provides Results in Less Than 24 Hours, Leading to Faster Diagnosis of Virus that Infects Millions of Americans Each Year
Test builds on company's suite of tests to evaluate immune function
Newly-Cleared Respiratory Viral Panel Enables Clinicians to Improve Patient Care through Fast and Accurate Laboratory Diagnosis